Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

September 15, 2021

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

September 07, 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

September 02, 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

September 01, 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

September 01, 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.

August 31, 2021

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

August 31, 2021

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

August 26, 2021

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

August 26, 2021

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

August 26, 2021

Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.

August 24, 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

August 24, 2021

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

August 19, 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

August 19, 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

August 19, 2021

Anita Kumar, MD, discusses future directions with pirtobrutinib in mantle cell lymphoma.

August 19, 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

August 19, 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

August 17, 2021

Anita Kumar, MD, discusses efforts made to address areas of unmet need in mantle cell lymphoma.

August 16, 2021

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

August 13, 2021

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.